文献速递青光眼

曼彻斯特青光眼强化转诊方案的临床有效性

Clinical effectiveness of the Manchester Glaucoma Enhanced Referral Scheme.
PubMed 文献 · Br J Ophthalmol · 2018-10-11

本研究评估曼彻斯特青光眼强化转诊方案(GERS)的临床有效性,估算假阳性率与假阴性率。研究期间共1404例患者接受GERS评估,651例(46.3%)转诊至医院眼科服务(HES),753例(53.6%)出院。307例可评估的转诊患者假阳性率为15.5%;在131例未转诊患者中,117例(89.3%)确认无需医院随访,14例(10.7%)需要随访,其中5例(3.8%)接受治疗,仅1例(0.8%)符合GERS转诊标准但未被转诊(真性假阴性),样本中未发现漏诊青光眼或非青光眼病变。结论认为曼彻斯特GERS是一种有效的青光眼过滤方案,假阳性率和假阴性率均较低。

要点

  • 曼彻斯特GERS方案假阳性率为15.5%,假阴性率低,仅0.8%符合转诊标准者未被转诊。
  • 未转诊患者中89.3%确认无需医院随访,10.7%需要随访,3.8%接受治疗。
  • 样本中未发现漏诊青光眼或非青光眼病变,支持该方案作为有效过滤工具。

核心结论

  • 曼彻斯特GERS是一种有效的青光眼过滤方案,假阳性率和假阴性率均较低。

研究设计与样本

  • 研究收集经GERS新转诊并在常规门诊评估的患者结局数据以确定假阳性率。
  • 对GERS评估后认为无需转诊的青光眼疑似患者,邀请其接受由青光眼专科验光师进行的参考标准检查,检查包括NICE推荐的所有评估要素,以确定假阴性率。
  • 另随机选取33例转诊和未转诊病例,由两名青光眼专科顾问眼科医师独立复核,以验证参考标准评估。

主要发现

  • 研究期间共1404例患者接受GERS评估,其中651例(46.3%)转诊至HES,753例(53.6%)出院。
  • 307例可评估的转诊至HES患者中,假阳性率为15.5%。
  • 131例(17.4%)未转诊至HES的患者接受了复核,其中117例(89.3%)确认无需医院随访,14例(10.7%)需要随访,包括5例(3.8%)接受治疗。
  • 该样本中仅1例(0.8%)符合GERS转诊标准但未被转诊(真性假阴性)。
  • 样本中未发现漏诊青光眼或非青光眼病变。

关键数值与推荐

  • GERS评估后转诊至HES的标准及未转诊者的参考标准检查均基于NICE推荐的评估要素。
  • 假阳性定义为转诊患者在首次就诊时被出院。
  • 真性假阴性定义为符合GERS转诊标准但未被转诊的患者。

临床怎么用

  • GERS可作为有效的青光眼转诊过滤工具,有助于减少不必要的医院转诊。
  • 该方案假阴性率低,未发现漏诊青光眼或非青光眼病变,支持其用于青光眼疑似患者的社区评估。

局限性

  • 假阴性率评估仅复核了17.4%的未转诊患者,可能存在选择偏倚。
  • 参考标准评估的验证仅基于33例随机选取的病例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glaucoma referral filtering schemes have operated in the UK for many years. However, there is a paucity of data on the false-negative (FN) rate. This study evaluated the clinical effectiveness of the Manchester Glaucoma Enhanced Referral Scheme (GERS), estimating both the false-positive (FP) and FN rates. METHOD: Outcome data were collected for patients newly referred through GERS and assessed in 'usual-care' clinics to determine the FP rate (referred patients subsequently discharged at their first visit). For the FN rate, glaucoma suspects deemed not requiring referral following GERS assessment were invited to attend for a 'reference standard' examination including all elements of assessment recommended by National Institute for Health and Care Excellence (NICE) by a glaucoma specialist optometrist. A separate 33 cases comprising randomly selected referred and non-referred cases were reviewed independently by two glaucoma specialist consultant ophthalmologists to validate the reference standard assessment. RESULTS: 1404 patients were evaluated in GERS during the study period; 651 (46.3%) were referred to the Hospital Eye Service (HES) and 753 (53.6%) were discharged. The FP rate in 307 assessable patients referred to the HES was 15.5%. This study reviewed 131 (17.4%) of those patients not referred to the HES through the GERS scheme; 117 (89.3%) were confirmed as not requiring hospital follow-up; 14 (10.7%) required follow-up, including 5 (3.8%) offered treatment. Only one patient (0.8%) in this sample met the GERS referral criteria and was not referred (true FN). There were no cases of missed glaucoma or non-glaucomatous pathology identified within our sample. CONCLUSION: The Manchester GERS is an effective glaucoma filtering scheme with a low FP and FN rate.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Gunn PJG, Marks JR, Konstantakopoulou E, et al. Clinical effectiveness of the Manchester Glaucoma Enhanced Referral Scheme. Br J Ophthalmol. 2018. PMID: 30309913. doi:10.1136/bjophthalmol-2018-312385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。